政大機構典藏-National Chengchi University Institutional Repository(NCCUR):Item 140.119/31008

政大機構典藏-National Chengchi University Institutional Repository(NCCUR):Item 140.119/31008

English | 正體中文 | 简体中文 | Post-Print筆數 : 27 | 全文笔数/总笔数 : 113318/144297 (79%)
造访人次 : 51078407 在线人数 : 969

RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.

搜寻范围

查询小技巧：

您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果

若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据

进阶搜寻

主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于政大典藏 ‧ 管理

到手机版

政大機構典藏 > 商學院 > 財務管理學系 > 學位論文 > Item 140.119/31008

请使用永久网址来引用或连结此文件: https://nccur.lib.nccu.edu.tw/handle/140.119/31008

题名:	美國食品暨藥物管理局藥物核准的宣告效果 Announcement Effect of Drug Approvals by FDA
作者:	丁秀文 Ting, Hsiu Wen
贡献者:	張元晨 Chang, Yuan chen 丁秀文 Ting, Hsiu Wen
关键词:	美國食品暨藥物管理局藥物宣告效果
日期:	2007
上传时间:	2009-09-14 09:03:07 (UTC+8)
摘要:	本文以事件研究法，討論美國食品暨藥物管理局在核准新藥上市的宣告效果。結果顯示在宣告日當天，各藥廠的異常報酬沒有顯著改變，但在宣告日的前五十天交易日可以觀察到顯著的累計異常報酬，根據美國食品暨藥物管理局的審核新藥流程以及學術性期刊對於新藥的臨床實驗數據探討，亦或是新聞對於新藥療效的提前揭露，推測皆會影響事件日之前的股價反應。進一步根據會計資料的觀察，新藥的核准上市，對於藥廠的營收雖沒有顯著改變，仍可以看出有增加的趨勢。最後，諸多新聞指出分析師對於新藥的審核過程中可以取得此藥物是否會通過美國食品暨藥物管理局的內線消息，結果顯示約有41％的分析師可以準確預測藥物是否可以通過，或許跟製藥業不同於其他產業的流程導致內線消息流出有關。 In this paper, we use event-study to estimate the stock price changes of Food and Drug Administration (FDA) decisions on new products for pharmaceutical companies. We find that FDA decisions have insignificant effects in all countries on the drug approval date. The insignificant price changes accompanying FDA announcements approval suggest that drug results have leaked to the market. It is quite possible that the results of advisory are open to public and advisory committee are held before FDA approval, advisory committee can be viewed as important news source of drug approval. After the drug approved by the FDA, the new drugs may bring additional income to the companies. Although the accounting data are insignificant at five percent significant level, we still can peek that the companies with new approval drug have their EPS increase. Besides, 41% of analyst rates the performance of next quarter better than actual EPS at that time. The reason can be the access of undisclosed information about successful approval of new drugs.
參考文獻:	Abrams S., 1994, The Publication of Clinical Facts: A Natural-Science View, International Journal of Psycho-Analysis, 75, 1201-1210 Acronym Required (http://www.acronymrequired.com/), 2005, Hedging Their Bets: Doctors, Pharmas and Investors Adams C, Brantner V., 2006, Estimating the cost of new drug development: is it really 802 million dollars? Health Affairs, 25(2), 420–8 Anand, Geeta and Smith, Randall, 2002, Trial Heat: Biotech Analysts Strive to Peek Inside Clinical Tests of Drugs-One Impersonated a Patient, One a Doctor; Firms Pay Physicians as Consultants- "Creativity Knows No Bounds`, The Wall Street Journal Arnst, Catherine, 2002, How Drug News Leaks to Investors, Business Week, 3781, 32-33 Baird, P., 2008, Clinical Trials and Industry, Science, 297, 2211 Barnett, Antony, 2003, Revealed: how drug firms `hoodwink` medical journals, from website: guardian.co.uk︱The Observer Bosch, Jean-Claude and Lee Insup, 1994, Wealth effects of Food and Drug Administration (FDA) Decisions, Managerial and Decision Economics, 15(6), 589-599 Brown, S.J. and Warner, J.B., Using Daily Stock Returns: the Case of Event Studies, Journal of Financial Economics, 14, 3-31 Church, Robert F., 2008, Pharmaceutical and Biotechnology Update, Pharmaceutical and Biotechnology Update, 1-3 Danzon, Patricia M., Epstein, Andrew and Nicholson, Sean, 2004, Mergers and Acquisitions in the Pharmaceutical and Biotech Industries, The Wharton School of University of Pennsylvania De Bondt, W. F. M. and Forbes, W. P., 1999, Herding in Analyst Earnings Forecasts: Evidence from the United Kingdom, European Financial Management 5, 143-163 DiMasi J, Hansen R and Grabowski H, 2003, The price of innovation: new estimates of drug development costs, Journal of Health Economics, 22(2), 151–85. Ferguson, James R., 1997, Biomedical Research and Insider Trading, The New England Journal of Medicine, 337, 631-634 Frank, Richard G., 2003, New estimates of drug development costs, Journal of Health Economics, 22(2), 325-330 Gad, Shayne Cox, 2005, Drug Discovery Handbook, Wiley-Interscience Hadzovic, 1997, Pharmacy and the great contribution of Arab-Islamic science to its development, Medicines Archive, 51 (1-2), 47-50 Huberman, Gur and T. Regev, 2001, Contagious Speculation and a Cure for Cancer: A non-event made stock prices soar, Journal of Finance, 56, 387-396 Kraljevic, Sandra, Stambrook, Peter J. and Pavelic, Kresimir, 2004, Accelerating drug discovery, EMBO Reports, 5(9), 837-842 Lenzer, Jeanne, 2005, What Can We Learn from Medical Whistleblowers? PLoS Medicine, 2(7), 583-586 Liu, Qiao, 2006, How Good is Good News? Technology Depth, Book-to-Market Ratios, and Innovative Events, Journal of Accounting Auditing and Finance, 21 (3), 293-321 Loomis, Carol J, 2008, Buffett’s biggest bets, Fortune McGuire, John L., Hasskarl, Horst, Bode, Gerd, Klingmann, Ingrid and Zahn, Manuel, 2007, Pharmaceuticals: General Survey, Ullmann`s Encyclopedia of Chemical Technology Moynihan R., 2008, Who pays for the pizza? Redefining the relationships between doctors and drug companies, British Medical Journal, 326(7400), 1193–1196 Pollack, Andrew, 2002, ImClone Stock Sales Disclosed, The New York Times Skolnick AA., 1998, SEC Going After Insider Trading Based on Medical Research Results, JAMA, 280(1), 10-11 Stewart, James B., 2007, Investors Should Heed Warren Buffett`s Free Advice, Smart money Stout, Hilary and Newman, Anne, 19 June 1991, FDA looks to stop leaks on drug stock, The Wall Street Journal Timmerman, Luke and Heath, David, 2005, Drug researchers leak secrets to Wall St., The Seattle Times Tufts Center for the Study of Drug Development Unknown, 2003, Rising Nicely, Economist, 367(8327), 55-56 Unknown, Drug Discovery & Development, 2005, industry trends Wold, Kirsten, Schneider, Chad, Shields, Brandon and Kerwin, Ricky, 2002, Prescription Drug Market, Economics 333
描述:	碩士國立政治大學財務管理研究所 95357022 96
資料來源:	http://thesis.lib.nccu.edu.tw/record/#G0095357022
数据类型:	thesis
显示于类别:	[財務管理學系] 學位論文

文件中的档案:

档案	大小	格式	浏览次数
index.html	0Kb	HTML2	234	检视/开启

在政大典藏中所有的数据项都受到原著作权保护.

社群 sharing

著作權政策宣告 Copyright Announcement

1.本網站之數位內容為國立政治大學所收錄之機構典藏，無償提供學術研究與公眾教育等公益性使用，惟仍請適度，合理使用本網站之內容，以尊重著作權人之權益。商業上之利用，則請先取得著作權人之授權。
The digital content of this website is part of National Chengchi University Institutional Repository. It provides free access to academic research and public education for non-commercial use. Please utilize it in a proper and reasonable manner and respect the rights of copyright owners. For commercial use, please obtain authorization from the copyright owner in advance.

2.本網站之製作，已盡力防止侵害著作權人之權益，如仍發現本網站之數位內容有侵害著作權人權益情事者，請權利人通知本網站維護人員(nccur@nccu.edu.tw)，維護人員將立即採取移除該數位著作等補救措施。
NCCU Institutional Repository is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff(nccur@nccu.edu.tw). We will remove the work from the repository and investigate your claim.

DSpace Software Copyright © 2002-2004 MIT & Hewlett-Packard / Enhanced by NTU Library IR team Copyright © - 回馈